News Room

Recent Press Releases
  • Graphic of two speech bubbles with three dots in each

    In Honor of Visionary Leader, PhRMA Announces the Kenneth C. Frazier PhRMA Scholars Program

    -

    Oct 21, 2021
    In honor of retiring PhRMA board member and visionary industry leader Ken Frazier, PhRMA today announced The Kenneth C. Frazier PhRMA Scholars Program to provide college scholarships to academically high achieving, low-income students in Washington, D.C. and in Ken’s hometown of Philadelphia, Pennsylvania.
  • Graphic of two speech bubbles with three dots in each

    New Survey Reveals Insurance Design Leads to Access and Affordability Issues for Most Vulnerable Patients

    -

    Oct 7, 2021
    Patients with serious chronic diseases report major challenges in getting the right medication because of insurance practices that force them to fail on less expensive medications first, and minority populations suffer disproportionately, according a new survey by PhRMA examining barriers people face in accessing health care and prescription medicines.
  • Graphic of two speech bubbles with three dots in each

    New Poll Shows that Support for Medicare “Negotiation” Plummets Once Americans Learn About the Policy Arguments

    -

    Sep 30, 2021
    A new Ipsos/PhRMA poll shows that initial support for Medicare “negotiation” evaporates once Americans are presented with arguments around the debate. Public opinion dips by as much as 51 points, overall, when Americans see arguments both for and against drug price “negotiations.”
  • Graphic of two speech bubbles with three dots in each

    PhRMA Litigation Challenging Constitutionality of Provisions in Arkansas Act 1103

    -

    Sep 29, 2021
    Today, the Pharmaceutical Research and Manufacturers of America (PhRMA) filed a complaint in the U.S. District Court for the Eastern District of Arkansas challenging provisions in Arkansas Act 1103 that seek to require manufacturers to provide federal 340B program pricing to Arkansas-based pharmacies contrary to federal statute.
  • Graphic of two speech bubbles with three dots in each

    PhRMA Statement on the Proposed Biosimilar User Fee Act (III) Performance Goals Letter

    -

    Sep 21, 2021
    Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO Stephen J. Ubl issued the following statement today on the release of the Biosimilar User Fee Act (III) Performance Goals Letter.
  • Graphic of two speech bubbles with three dots in each

    PhRMA’s Steve Ubl Says White House Drug Pricing Proposal “Not a Serious Plan” to Lower What Patients Pay

    -

    Sep 9, 2021
    Pharmaceutical Research and Manufacturers of America (PhRMA) president and CEO Stephen J. Ubl made the following statement in response to the administration’s drug pricing plan.
  • Graphic of two speech bubbles with three dots in each

    PhRMA’s Steve Ubl: CBO Report Makes Clear “Patients Face Future with Less Hope Under Congress’ Drug Pricing Plan”

    -

    Aug 27, 2021
    Pharmaceutical Research and Manufacturers of America president and CEO Stephen J. Ubl made the following statement after the nonpartisan Congressional Budget Office (CBO) released a new report that found policies like those included in Speaker Nancy Pelosi’s drug pricing plan (H.R. 3) will lead to 60 fewer new treatments in the next three decades.
  • Graphic of two speech bubbles with three dots in each

    PhRMA Statement on the Proposed Prescription Drug User Fee Act VII Performance Goals Letter

    -

    Aug 23, 2021
    For nearly 30 years, the Prescription Drug User Fee Act (PDUFA) has helped the U.S. Food and Drug Administration (FDA) fulfill its central mission to help protect and advance the public health by allowing the Agency to keep pace with the number and complexity of innovative drugs and biologics entering the regulatory review pipeline.
Search Results for ""
  • refreshdiseases
    COVID-19
  • refreshtopics
    340B
  • refreshtopics
    About
  • refreshtopics
    Access to Medicines
  • refreshtopics
    Adherence
  • refreshtopics
    Advances in Treatment
  • refreshdiseases
    HIV AIDs
  • refreshdiseases
    Alzheimers Disease
  • refreshtopics
    AMR
  • refreshtopics
    Codes and Guidelines
  • refreshdiseases
    Heart Disease and Stroke
  • refreshtopics
    Cost and Value
  • refreshtopics
    Biologic and Biosimilars
  • refreshtopics
    Research and Development
  • refreshdiseases
    Rheumatoid Arthritis
  • refreshtopics
    Patient Assistance
  • refreshdiseases
    Asthma
  • refreshtopics
    Part B
  • refreshtopics
    Research in Your Backyard
  • refreshtopics
    Better Way
  • refreshtopics
    Biomarkers
  • refreshdiseases
    Hepatitis C
  • refreshdiseases
    Cancer
  • refreshdiseases
    Cardiovascular Disease
  • refreshtopics
    Value-Driven Health Care
  • refreshdiseases
    Chronic Disease
  • refreshtopics
    Clinical Trials
  • refreshtopics
    Contact Us
  • refreshdiseases
    COPD
  • refreshtopics
    Coronavirus
  • refreshtopics
    Health Coverage Hurdles
  • refreshtopics
    Insurance Coverage
  • refreshtopics
    Part D
  • refreshtopics
    Medicines in Development
  • refreshdiseases
    Diabetes
  • refreshtopics
    Digital
  • refreshdiseases
    Parkinsons Disease
  • refreshtopics
    Disease
  • refreshdiseases
    Rare Diseases
  • refreshdiseases
    Neurological Disorders
  • refreshdiseases
    Ebola
  • refreshtopics
    Economic Impact
  • refreshtopics
    Equity
  • refreshtopics
    Events
  • refreshtopics
    FDA
  • refreshdiseases
    Mental Health
  • refreshtopics
    Innovation
  • refreshtopics
    Intellectual Property
  • refreshtopics
    International
  • refreshtopics
    Leaders
  • refreshtopics
    Medicaid
  • refreshtopics
    Medicare
  • refreshtopics
    Personalized Medicine
  • refreshtopics
    Medicine Safety
  • refreshtopics
    Members
  • refreshtopics
    PhRMA Membership
  • refreshtopics
    Mission
  • refreshdiseases
    Multiple Sclerosis
  • refreshtopics
    Terms of Service
  • refreshdiseases
    Osteoporosis
  • refreshtopics
    Patients
  • refreshtopics
    PDUFA
  • refreshtopics
    Privacy Policy
  • refreshtopics
    Report
  • refreshtopics
    Resources
  • refreshtopics
    Science
  • refreshtopics
    Search
  • refreshtopics
    Sign Up
  • refreshtopics
    Speeches
  • refreshtopics
    Stem
  • refreshtopics
    Trade
{count} Resources found
Viewing {showCount} of {count} results